<DOC>
	<DOCNO>NCT02170025</DOCNO>
	<brief_summary>Assessment safety , tolerability early sign efficacy three time day orally administer BAY63-2521 adult delta F508 homozygous Cystic Fibrosis patient treatment Orkambi</brief_summary>
	<brief_title>Early Signs Efficacy Study With Riociguat Adult Homozygous Delta F508 Cystic Fibrosis Patients</brief_title>
	<detailed_description>The study consist two part . The first part double-blind , randomize placebo-controlled . The second part open-label study design . In part 1 patient Orkambi CFTR-modulators exclude . In part 2 patient Orkambi allow include certain condition .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Signed informed consent available study specific test procedure perform Patients must least 18 year age time inclusion ( i.e . upon signature inform consent ) Patient diagnose Cystic Fibrosis accord standard criterion ( i.e . either elevate sweat chloride content 60 mmol/ L and/ genetic test ) Patient homozygous deltaF508 mutation Patient mildtomoderate stage lung disease determine FEV1 ( FEV1 40 100 % predict ) Patient stable condition lung disease ( ongoing recent pulmonary exacerbation change current treatment ) within last 4 week prior screen Ability willingness understand follow study procedure entire study Patients smoke . Patients history smoking include , refrain smoke last 3 month . If patient start smoke study participation , he/ need exclude consider drop Body mass index ( BMI ) : ≥ 16 kg/ m² ( calculated divide patient 's weight square his/ height [ kg/ m2 ] ) Inclusion criterion valid study part 1 : Women childbearing potential must agree use adequate contraception sexually active . 'Adequate contraception ' define one highly effective form contraception ( intrauterine device [ IUD ] , contraceptive implant tubal sterilization ) combination method ( hormone method barrier method ) . If partner 's vasectomy choose method contraception partner document azoospermia , hormone barrier method must use combination . Adequate contraception require signing informed consent form 4 week last study drug administration Inclusion criterion valid study part 2 : Women childbearing potential must agree use adequate contraception sexually active . 'Adequate contraception ' define one highly effective form contraception ( intrauterine device [ IUD ] , contraceptive implant tubal sterilization ) combination method ( hormone method barrier method ) . For patient Orkambi hormonal method ( include hormonal oral contraceptive ) accept study . They need choose nonhormonal method . If partner 's vasectomy choose method contraception partner document azoospermia , hormone barrier method must use combination . Adequate contraception require signing informed consent form 4 week last study drug administration Patients receive Orkambi ( Lumcaftor + Ivacaftor ) part standard care need stable Orkambi treatment least 3 month prior screen ( patient Lumacaftor and/or Ivacaftor exclude part 1 ) Patients Cystic Fibrosis background homozygous deltaF508 mutation Exclusion criterion valid study part 1 : Patients receive treatment Lumacaftor and/ Ivacaftor Active state hemoptysis pulmonary hemorrhage , include event manage bronchial artery embolization . Also history moderate hemoptysis within 3 month prior inclusion Any history pneumothorax , bronchial artery embolization massive hemoptysis . Massive hemoptysis define acute bleeding &gt; 240 mL 24hour period recurrent bleed &gt; 100 mL/ several day A positive sputum culture Burkholderia cenocepacia , Burkholderia dolosa , and/ Mycobacterium absessus either currently within previous year Active allergic bronchopulmonary aspergillosis Current pulmonary exacerbation Known history solid organ transplantation Known history form pulmonary hypertension Clinically relevant deviation screen laboratory parameter reference range outside expect change Cystic Fibrosis patient , especially hemoglobin value 110 g/L creatinine clearance base CockcroftGault formula &lt; 15 ml/ min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cystic fibrosis</keyword>
	<keyword>delta F508</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Sweat Chloride</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>